Mosunetuzumab Medicine 07 December 2021 Extended indication Refractory follicular lymphoma (FL) Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Mosunetuzumab Domain Oncology and Hematology Reason of inclusion New medicine (specialité) Main indication Indolent non-Hodgkin’s lymphoma Extended indication Refractory follicular lymphoma (FL) Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Genentech Portfolio holder Mechanism of action Unknown Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulant. Registration Registration route Centralised (EMA) Type of trajectory Accelerated assessment Particularity Unknown ATMP Unknown Submission date November 2021 Expected Registration July 2022 Orphan drug Unknown Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times every 4 weeks Dosage per administration References NCT04712097 Additional remarks Patients will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12 Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks